Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ:WBD) to Peer Perform from Underperform following its Q3 results last week, and assigned a fair value range of $ ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and ...

Wolfe Research initiated coverage of StandardAero (SARO) with an Outperform rating and $34 price target The firm says disruption in all areas of the plane manufacturer landscape make it a very ...